STOK Stock Up 39% after 5-Day Win Streak
Stoke Therapeutics (STOK) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 39% return. The company has gained about $391 Mil in value over the last 5 days, with its current market capitalization at about $1.0 Bil. The stock remains 65.1% above its value at the end of 2024. This compares with year-to-date returns of 9.7% for the S&P 500.
STOK develops novel antisense oligonucleotide medicines targeting severe genetic diseases, with a lead clinical candidate in phase I/IIa trials for treating Dravet syndrome epilepsy. After this rally, is STOK still a buy – or is it time to lock in gains? Deep dive with Buy or Sell STOK.
Comparing STOK Stock Returns With The S&P 500
The following table summarizes the return for STOK stock vs. the S&P 500 index over different periods, including the current streak:
- Broadcom Stock: 7 Straight Green Days, Up 16%
- Verizon Communications Was The Bargain A Year Ago. Now It Carries The Premium Over AT&T
- Cisco Stock Is Finally Pricing In A New Growth Story
- PYPL Showered Owners With Cash. The Stock Still Lagged The Market
- META Stock Returns To Familiar Ground
- UNH Leads Its Peer Group. You Pay For That
| Return Period | STOK | S&P 500 |
|---|---|---|
| 1D | 6.1% | -0.3% |
| 5D (Current Streak) | 39.0% | 0.9% |
| 1M (21D) | 47.4% | 2.4% |
| 3M (63D) | 89.1% | 9.0% |
| YTD 2025 | 65.1% | 9.7% |
| 2024 | 109.7% | 23.3% |
| 2023 | -43.0% | 24.2% |
| 2022 | -61.5% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has STOK behaved after prior drops? See STOK Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 35 S&P constituents with 3 days or more of consecutive gains and 27 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 9 | 24 |
| 4D | 16 | 2 |
| 5D | 4 | 0 |
| 6D | 1 | 1 |
| 7D or more | 5 | 0 |
| Total >=3 D | 35 | 27 |
Key Financials for Stoke Therapeutics (STOK)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $8.8 Mil | $36.6 Mil |
| Operating Income | $-114.8 Mil | $-101.4 Mil |
| Net Income | $-104.7 Mil | $-89.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $158.6 Mil | $13.8 Mil |
| Operating Income | $111.2 Mil | $-27.3 Mil |
| Net Income | $112.9 Mil | $-23.5 Mil |
While STOK stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.